Product Highlight-Victoza

27 Sep 2018
Product Highlight-Victoza
VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk

Victoza is now approved in Malaysia for prevention of
cardiovascular events.1

• The only GLP-1 proven to prevent CV events – 22% relative risk reduction in CV death2
• Unsurpassed HbA1c efficacy across 14 head-to-head trials3-6
• Unsurpassed weight loss across 14 head-to-head trials3-6


References:
1. Victoza Malaysia Prescribing Information.
2. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med.2016;375(4):311-322.
3. Pratley R, Nauck M, Bailey T, et al; for the 1860-LIRA-DPP4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes; a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397-407.
4. Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomised controlled clinical trial. Diabetes Care. 2016;39(9):1501-1509.
5. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;38(9861):117-124.
6. References on file.

Further information is available in section 11b and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Editor's Recommendations